What is NewAmsterdam Pharma Company N.V.'s Shariah compliance score?

NewAmsterdam Pharma Company N.V.'s (NAMS) compliance score is being calculated. Check HalalScreener.app for the latest AAOIFI screening results.

Does NewAmsterdam Pharma Company N.V. pass AAOIFI screening?

NewAmsterdam Pharma Company N.V. (NAMS) does not pass AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (NAMS: 0.0%), (3) interest-bearing deposits below 30% (NAMS: 25.6%), and (4) prohibited income below 5% (NAMS: 246.8%). HalalScreener provides free AAOIFI screening for 10,000+ stocks at halalscreener.app.

How much purification is needed for NewAmsterdam Pharma Company N.V. stock?

NewAmsterdam Pharma Company N.V. (NAMS) has a non-permissible income ratio of 246.84%. Muslim investors should purify this percentage of any dividends received and capital gains realized from NAMS shares by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification automates this calculation using the latest financial data.

Where can I screen NewAmsterdam Pharma Company N.V. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for NewAmsterdam Pharma Company N.V. (NAMS) and 10,000+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows all financial ratios transparently. No credit card or signup required for basic screening. HalalScreener also includes an AI Islamic Scholar for follow-up questions about NAMS's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

Is NewAmsterdam Pharma Company N.V. (NAMS) halal? Not Halal. Based on AAOIFI screening, NewAmsterdam Pharma Company N.V. passes the business activity screen but fails financial ratio screens with a compliance score of 0/100 (Grade: F).

NAMS: Is NewAmsterdam Pharma Company N.V. Halal?

Not Halal

NewAmsterdam Pharma Company N.V.

NASDAQHealthcareUS

$31.71

-0.25%

AvoidBorderlineClean

About NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Jun 18, 2026

Non-Compliant

Fails Shariah screening

0Score

Business Activity Screen

Passed

Checks if the business is involved in prohibited activities (alcohol, gambling, pork, conventional banking, etc.)

Financial Ratio Screen

Failed

Financial ratios must be below AAOIFI thresholds

Debt / Market Cap0.0% / 30.0%

Compliance History

Not Halal, unchanged since May 2026.

No status changes recorded since we began tracking.

Tracked since May 2026. Updates automatically on each re-screen.

Screened: Jun 18, 2026Fiscal: Q1 2026Source: EDGAR

Financial Overview

Market Cap

3.7B

Price

$31.71

Sector

Healthcare

Industry

Biotechnology

Halal Alternatives in Healthcare

This stock is not Shariah-compliant. Here are halal alternatives from the same sector, ranked by compliance score:

0001.KLA+

Supercomnet Technologies Bhd

$0.54

+0.00%

0002.KLA+

Kotra Industries Bhd

$3.75

+0.00%

0075.KLA+

LYC Healthcare Bhd

$0.02

+0.00%

0101.KLA+

TMC Life Sciences Bhd

$0.45

+0.00%

0155.KLA+

Malaysian Genomics Resource Centre Bhd

$0.27

+0.00%

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

B+

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

B+

Free · No credit card required

Track NAMS and 10,000+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

10,000+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is NewAmsterdam Pharma Company N.V. (NAMS) halal to invest in?

NewAmsterdam Pharma Company N.V. (NAMS) is rated Not Halal under AAOIFI Standard 21 screening. It fails either the business activity screen (primary involvement in prohibited sectors such as conventional banking, alcohol, or gambling) or one of the quantitative financial ratio thresholds. Muslim investors should avoid or exit this position.

Why did NewAmsterdam Pharma Company N.V. get a F compliance rating?

NewAmsterdam Pharma Company N.V. (NAMS) received a grade of F (Non-Compliant) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 0.0% (limit 30%); interest-bearing deposits of 25.6% (limit 30%); prohibited income of 246.84% (limit 5%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change NewAmsterdam Pharma Company N.V.'s Shariah verdict?

NewAmsterdam Pharma Company N.V.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is NewAmsterdam Pharma Company N.V. re-screened for Shariah compliance?

NewAmsterdam Pharma Company N.V. (NAMS) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Jun 18, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.